Wednesday, May 24, 2017 @ 8 am Pacific, 9 am Mountain, 10 am Central, 11 am Eastern
Call In by Phone to Listen Live: (347) 637-2631 or Listen Live Via Computer
Many patients are familiar with the monoclonal antibodies daratumumab and elotuzumab. These target a specific protein on the surface of myeloma cells. A new drug is in development (called EM801) to target both a protein on the surface of myeloma cells (BCMA) while also activating the immune system’s T cells. This is called a bi-specific antibody, going after two targets at the same time. Learn more about how this approach by German researchers Anja Seckinger, MD and Dirk Hose, MD of the University of Heidelberg could provide an off-the-shelf immunotherapy for myeloma patients to give myeloma a double punch.
Thanks to our episode sponsor, Takeda Oncology.